Guerbet Agrees to Acquire Accurate Medical Therapeutics


January 8, 2018—Guerbet, a France-based company specializing in contrast agents and solutions for medical imaging, announced that it has entered into an agreement to acquire Israel-based Accurate Medical Therapeutics, which develops microcatheters used in interventional radiology, including use in embolization procedures to treat tumors and vascular aneurysms.

Accurate Medical Therapeutics, which was founded in 2015, will retain its structure in Israel and will continue to be led by Cofounder and Chief Executive Officer Eran Miller. Michael Tal, MD, is also Cofounder of Accurate. Under this agreement, Guerbet will acquire 100% of Accurate's capital share, with an initial payment of €19.5 million and additional payments based on the achievement of regulatory and commercial objectives.

According to the Guerbet, Accurate Medical Therapeutics offers two series of microcatheters. The devices in the first series are designed for optimization of intra-arterial navigation, even in tortuous vascular networks and hard-to-access lesions. The devices in the second series possess the same optimized navigation qualities and incorporate antireflux technology. Side holes located in the terminal part of the catheter create a fluid barrier preventing reflux of embolization microspheres. This technology allows for the administration of more embolization microspheres to the targeted treatment area, while also preventing them from refluxing upstream to arteries irrigating healthy tissues.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.